SAELENS Karen (CAB-VON DER LEYEN)

From: Giuliana Pennisi < gpennisi@medicinesforeurope.com>

Sent: vendredi 25 septembre 2020 10:52

To: VANDENBERGHE Kurt (CAB-VON DER LEYEN)

Cc: SG COURRIER PRESIDENT et VICE-PRESIDENTS; SAELENS Karen (CAB-VON DER

LEYEN); Adrian van den Hoven

Subject: URGENT! RE: Medicines for Europe meeting request | Pharma strategy & Covid19

lessons learned + 2nd Wave pandemic prepardness (Ares(2020)4122906)

Importance: High

Dear Mr. Vandenberghe,

I am writing to you again as regard two urgent issues related to the pharmaceutical sector.

The first one concerns the recent State of the Union address. Medicines for Europe followed closely the Plenary Session, while we applaud President von der Leyen where she stressed the need for a stronger European Health Union and recognize the importance of an European BARDA, we acknowledge the possibility to have **strategic stockpiling** to address supply chain dependencies, notably for pharmaceutical products. In this context, I would like to inform you that Medicines for Europe is finalising a proposal on a European stockpiling, by taking into account the technicalities related to the pharmaceutical industry and its supply chain. Hence, we would be glad to illustrate President von der Leyen either you our proposal in the incoming weeks.


Furthermore, I would like to emphasize the importance of the upcoming **pharmaceutical and industrial strategies** and their key role to solve vulnerabilities of the current supply chain to ensure equitable access to medicines while enabling the EU to face current and future health crisis. To do so, it is key to consider the pharmaceutical sector in its integrity (on and off patent) and to reflect this in the future policies, considering the fact that our sector which may not have the same commercial value as other pharma sectors but it supplies close to 70% of prescription medicines meaning it is by far the most impactful on public health.

Despite the fact that we share several priorities with our counterpart, it also important to have in mind that our companies operate in very different circumstances and for them is vital to operate with sustainable market conditions, healthy competition at the end of exclusivity rights, targeted uptake measures for generic and biosimilar medicines and several other measures that my President would be glad to illustrate you at your earliest convenience.

I know that both the President and yourself have already rejected our meeting request, but we would love to have the same speaking rights that you have conceded to the other side of the industry considering that soon is expected the publication of the pharmaceutical and industrial strategies and the Commission, in line with the EU Treaties, is going to regulate directly our sector and that every change could be of crucial importance taking also into account the historical momentum that we are facing.

Thanking you in advance for the attention that you would pose to my request, I remain at your disposal for any further information you may need.

Kindest regards, Giuliana Pennisi



Giuliana Pennisi Senior Manager Public Affairs M: +32 (0) 488 15 00 24

Transparency register: 48325781850-28



From: Giuliana Pennisi

Sent: Tuesday, 1 September 2020 19:11 **To:** Kurt.Vandenberghe@ec.europa.eu

Cc: Courpre@ec.europa.eu; Adrian van den Hoven <adrian@medicinesforeurope.com>

Subject: RE: Medicines for Europe meeting request | Pharma strategy & Covid19 lessons learned + 2nd Wave

pandemic prepardness (Ares(2020)4122906)


Dear Mr. Vandenberghe,

I would like to thank you for your kind and prompt reply. We totally understand that President von der Leyen's agenda is very busy at the current moment.

Due to the sensitivity of the subject of our meeting request, especially considering the historical momentum that we are facing, would it be possible to schedule a virtual meeting with you instead?

I warmly thank you for the attention thank you would pose to our request, we remain at your disposal for any further information you may need.

Kindest regards, Giuliana Pennisi



Giuliana Pennisi Senior Manager Public Affairs M: +32 (0) 488 15 00 24 Transparency register: 48325781850-28



From: Karen.Saelens@ec.europa.eu < Karen.Saelens@ec.europa.eu > On Behalf Of

<u>Kurt.Vandenberghe@ec.europa.eu</u> **Sent:** Tuesday, 1 September 2020 17:40

To: Giuliana Pennisi < gpennisi@medicinesforeurope.com >

Cc: Courpre@ec.europa.eu

Subject: RE: Medicines for Europe meeting request | Pharma strategy & Covid19 lessons learned + 2nd Wave pandemic prepardness (Ares(2020)4122906)

Dear Ms Pennisi,

President von der Leyen would like to thank you for your e-mail kindly requesting a meeting with Medicines for Europe President, Mr. Christoph Stoller, which could take place in person or virtually on a date to be convened in order to discuss your key policy recommendations that are also outlined in the official feedback to the pharmaceutical strategy

roadmap and in your two policy papers 'Medicines for Europe lessons learned from Covid-19' and 'Roadmap for Medicines Manufacturing Leadership', which you kindly attached to your e-mail.

Regrettably, despite her interest in discussing these important and pertinent topics, the President is unable to give a positive response to your request due to a very busy schedule during the current period.

Thank you in advance for your understanding.

Thank you also for sharing a copy of the letter that you sent last week to the Commissioner for Health, Ms Stella Kyriakides, as well as to the German Presidency to the European Union, regarding preparations for a second wave of the COVID-19 pandemic.

Yours sincerely,

Kurt Vandenberghe

Green Deal Adviser



European Commission

Cabinet of President Ursula von der Leyen 200 Rue de la Loi Berlaymont (BERL) 13/152 1049 Brussels/Belgium +32 229-69207 kurt.vandenberghe@ec.europa.eu http://ec.europa.eu/research

From: Giuliana Pennisi <gpennisi@medicinesforeurope.com>

Sent: Tuesday, August 4, 2020 6:09 PM

To: EC PRESIDENT VDL <EC-PRESIDENT-VDL@ec.europa.eu>

Cc: SEIBERT Bjoern (CAB-VON DER LEYEN) < Bjoern.SEIBERT@ec.europa.eu >; RISO Stephanie (CAB-VON DER LEYEN) < Stephanie.Riso@ec.europa.eu >; VANDENBERGHE Kurt (CAB-VON DER LEYEN) < Kurt.Vandenberghe@ec.europa.eu >; TOVSAK PLETERSKI Mary Veronica (CAB-VON DER LEYEN) < Mary-Veronica.TOVSAK-PLETERSKI@ec.europa.eu >; HAUGAARD Per (CAB-VON DER LEYEN) < Per.Haugaard@ec.europa.eu >; VILA NUNEZ Sonia (CAB-VON DER LEYEN) < Sonia.VILA-NUNEZ@ec.europa.eu >; ZIEGER Corina (CAB-VON DER LEYEN) < Corina.ZIEGER@ec.europa.eu >; WHELAN Anthony (CAB-VON DER LEYEN) < Anthony.WHELAN@ec.europa.eu >; Adrian van den Hoven < adrian@medicinesforeurope.com >

Subject: Medicines for Europe meeting request | Pharma strategy & Covid19 lessons learned + 2nd Wave pandemic prepardness

Importance: High

Dear President von der Leyen,

As you know, Medicines for Europe represents the European off-patent medicines manufacturers. Generic, biosimilar and value added medicines are almost 70% of prescribed medicines in the European Union and are critical to equitable access as well as to public health, as demonstrated by our industry's role in dramatically increasing the supply of medicines for Covid-19.

I am writing to you as regard to the forthcoming publication of the pharmaceutical strategy "Timely patient access to affordable medicines" by the European Commission.

Medicines for Europe believes that to deliver equitable patient access to medicines and to contribute to healthcare system sustainability, the pharmaceutical strategy should prioritise sustainable economic, regulatory and industrial off patent medicines policies as well as including key lessons

learned from Covid-19 pandemic. In this regard, Medicines for Europe President, Mr. Christoph Stoller, would be honored to schedule a meeting with you (virtual either face to face), at your earliest convenience, to illustrate our key policy recommendations that you can find summarised in the official feedbacks to the pharmaceutical strategy roadmap and extensively described in our two policy papers Medicines for Europe lessons learned from Covid-19 and Roadmap for Medicines Manufacturing Leadership (you can also find a copy enclosed).

I take the chance of this e-mail to share with you a copy of the letter that we have sent last week to the Commissioner for Health, Ms. Stella Kyriakides, as well as to the German Presidency to the European Union on the second wave pandemic preparedness. At our meeting, we believe that it would be important to have an exchange of view also on such important issue.

Thanking you in advance for the attention that you would pose to our request, we remain at your disposal for any further information you may need.

Yours sincerely, Giuliana Pennisi



Giuliana Pennisi Senior Manager Public Affairs M:+32 (0) 488 15 00 24 Transparency register: 48325781850-28 medicines

or europe

Disclaimer

The information contained in this communication from the sender is confidential. It is intended solely for use by the recipient and others authorized to receive it. If you are not the recipient, you are hereby notified that any disclosure, copying, distribution or taking action in relation of the contents of this information is strictly prohibited and may be unlawful.

This email has been scanned for viruses and malware, and may have been automatically archived by **Mimecast Ltd**, an innovator in Software as a Service (SaaS) for business. Providing a **safer** and **more useful** place for your human generated data. Specializing in; Security, archiving and compliance. To find out more <u>Click Here</u>.

Disclaimer

The information contained in this communication from the sender is confidential. It is intended solely for use by the recipient and others authorized to receive it. If you are not the recipient, you are hereby notified that any disclosure, copying, distribution or taking action in relation of the contents of this information is strictly prohibited and may be unlawful.

This email has been scanned for viruses and malware, and may have been automatically archived by **Mimecast Ltd**, an innovator in Software as a Service (SaaS) for business. Providing a **safer** and **more useful** place for your human generated data. Specializing in; Security, archiving and compliance. To find out more <u>Click Here</u>.